000169324 001__ 169324
000169324 005__ 20240229140923.0
000169324 0247_ $$2doi$$a10.1080/15592294.2021.1940644
000169324 0247_ $$2pmid$$apmid:34159881
000169324 0247_ $$2ISSN$$a1559-2294
000169324 0247_ $$2ISSN$$a1559-2308
000169324 037__ $$aDKFZ-2021-01416
000169324 041__ $$aEnglish
000169324 082__ $$a610
000169324 1001_ $$aSchröder, Rieke$$b0
000169324 245__ $$aThe epigenetics of breast cancer - Opportunities for diagnostics, risk stratification and therapy.
000169324 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2022
000169324 3367_ $$2DRIVER$$aarticle
000169324 3367_ $$2DataCite$$aOutput Types/Journal article
000169324 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1656426637_18202
000169324 3367_ $$2BibTeX$$aARTICLE
000169324 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169324 3367_ $$00$$2EndNote$$aJournal Article
000169324 500__ $$a2022 Jun;17(6):612-624
000169324 520__ $$aThe stage and molecular pathology-dependent prognosis of breast cancer, the limited treatment options for triple-negative carcinomas, as well as the development of resistance to therapies illustrate the need for improved early diagnosis and the development of new therapeutic approaches. Increasing data suggests that some answers to these challenges could be found in the area of epigenetics. In this study, we focus on the current research of the epigenetics of breast cancer, especially on the potential of epigenetics for clinical application in diagnostics, risk stratification and therapy. The differential DNA methylation status of specific gene regions has been used in the past to differentiate breast cancer cells from normal tissue. New technologies as detection of circulating nucleic acids including microRNAs to early detect breast cancer are emerging. Pattern of DNA methylation and expression of histone-modifying enzymes have been successfully used for risk stratification. However, all these epigenetic biomarkers should be validated in larger clinical studies. Recent preclinical and clinical studies show a therapeutic benefit of epigenetically active drugs for breast cancer entities that are still difficult to treat (triple negative, UICC stage IV). Remarkably, epigenetic therapies combined with chemotherapies or hormone-based therapies represent the most promising strategy. At the current stage, the integration of epigenetic substances into established breast cancer therapy protocols seems to hold the greatest potential for a clinical application of epigenetic research.
000169324 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000169324 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169324 650_7 $$2Other$$aDNA methylation
000169324 650_7 $$2Other$$aEpigenetic
000169324 650_7 $$2Other$$abreast cancer
000169324 650_7 $$2Other$$ahistone acetylation
000169324 650_7 $$2Other$$ahistone methylation
000169324 7001_ $$aIllert, Anna-Lena$$b1
000169324 7001_ $$aErbes, Thalia$$b2
000169324 7001_ $$0P:(DE-He78)b830b7dd76ce1306bd1af811671b773b$$aFlotho, Christian$$b3$$udkfz
000169324 7001_ $$0P:(DE-HGF)0$$aLübbert, Michael$$b4
000169324 7001_ $$00000-0002-8287-5673$$aDuque-Afonso, Jesús$$b5
000169324 773__ $$0PERI:(DE-600)2248598-3$$a10.1080/15592294.2021.1940644$$gp. 1 - 13$$n6$$p612-624$$tEpigenetics$$v17$$x1559-2308$$y2022
000169324 909CO $$ooai:inrepo02.dkfz.de:169324$$pVDB
000169324 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b830b7dd76ce1306bd1af811671b773b$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169324 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169324 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000169324 9130_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000169324 9141_ $$y2021
000169324 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000169324 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000169324 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000169324 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIGENETICS-US : 2021$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-13
000169324 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-13
000169324 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000169324 980__ $$ajournal
000169324 980__ $$aVDB
000169324 980__ $$aI:(DE-He78)FR01-20160331
000169324 980__ $$aUNRESTRICTED